{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:56:48Z","timestamp":1776495408890,"version":"3.51.2"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017443","name":"Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017443","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003896","name":"Henry M. Jackson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009898","name":"Defense Health Agency","doi-asserted-by":"publisher","award":["W81XWH-18-2-0040"],"award-info":[{"award-number":["W81XWH-18-2-0040"]}],"id":[{"id":"10.13039\/100009898","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010203","name":"Walter Reed Army Institute of Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016156","name":"U.S. Army Medical Research and Development Command","doi-asserted-by":"publisher","award":["W81-XWH-18-C-0337"],"award-info":[{"award-number":["W81-XWH-18-C-0337"]}],"id":[{"id":"10.13039\/100016156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ebiom.2023.104683","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T18:58:00Z","timestamp":1688497080000},"page":"104683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Humoral immune responses associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US military population"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4576-4277","authenticated-orcid":false,"given":"Gregory D.","family":"Gromowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila Macedo","family":"Cincotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3348-1632","authenticated-orcid":false,"given":"Jocelyn","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Swafford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael K.","family":"McCracken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dante","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Enoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey","family":"Storme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Darden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila","family":"Peel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Epperson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"McKee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Currier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Okulicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-3414","authenticated-orcid":false,"given":"Dominic","family":"Paquin-Proulx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1981-7366","authenticated-orcid":false,"given":"Jessica","family":"Cowden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Peachman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ebiom.2023.104683_bib1","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"7911","key":"10.1016\/j.ebiom.2023.104683_bib2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41586-022-04690-5","article-title":"Defining the risk of SARS-CoV-2 variants on immune protection","volume":"605","author":"DeGrace","year":"2022","journal-title":"Nature"},{"issue":"7830","key":"10.1016\/j.ebiom.2023.104683_bib3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"issue":"6505","key":"10.1016\/j.ebiom.2023.104683_bib4","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"issue":"7885","key":"10.1016\/j.ebiom.2023.104683_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-021-04017-w","article-title":"Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy","volume":"599","author":"Yamin","year":"2021","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104683_bib6","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/s41590-021-01068-z","article-title":"Low-dose in\u00a0vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations","volume":"22","author":"Dussupt","year":"2021","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.ebiom.2023.104683_bib7","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.cell.2021.02.026","article-title":"Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection","volume":"184","author":"Winkler","year":"2021","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104683_bib8","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.immuni.2021.08.015","article-title":"Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy","volume":"54","author":"Ullah","year":"2021","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104683_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.13091","article-title":"Correlates of protection against SARS-CoV-2 infection and COVID-19 disease","volume":"310","author":"Goldblatt","year":"2022","journal-title":"Immunol Rev"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104683_bib10","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.chom.2021.02.020","article-title":"The variant gambit: COVID-19's next move","volume":"29","author":"Plante","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104683_bib11","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.3390\/v14092009","article-title":"The rise and fall of SARS-CoV-2 variants and ongoing diversification of Omicron","volume":"14","author":"Wiegand","year":"2022","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104683_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02979-21","article-title":"The impact of evolving SARS-CoV-2 mutations and variants on COVID-19 vaccines","volume":"13","author":"McLean","year":"2022","journal-title":"mBio"},{"issue":"10","key":"10.1016\/j.ebiom.2023.104683_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105044","article-title":"The mechanisms of immune response and evasion by the main SARS-CoV-2 variants","volume":"25","author":"Chen","year":"2022","journal-title":"iScience"},{"issue":"26","key":"10.1016\/j.ebiom.2023.104683_bib14","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1016\/j.vaccine.2022.04.069","article-title":"Assessing vaccine effectiveness against severe COVID-19 disease caused by Omicron variant. Report from a meeting of the World Health Organization","volume":"40","author":"Feikin","year":"2022","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104683_bib15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by covid-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10328","key":"10.1016\/j.ebiom.2023.104683_bib16","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104683_bib17","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41591-021-01575-4","article-title":"Viral loads of delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2","volume":"27","author":"Levine-Tiefenbrun","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104683_bib18","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/s41467-022-28936-y","article-title":"Waning of SARS-CoV-2 booster viral-load reduction effectiveness","volume":"13","author":"Levine-Tiefenbrun","year":"2022","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.ebiom.2023.104683_bib19","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/s41591-022-01816-0","article-title":"Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, delta or Omicron SARS-CoV-2","volume":"28","author":"Puhach","year":"2022","journal-title":"Nat Med"},{"issue":"26","key":"10.1016\/j.ebiom.2023.104683_bib20","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1056\/NEJMc2102507","article-title":"Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated persons","volume":"385","author":"Kissler","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104683_bib21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41467-020-20568-4","article-title":"Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)","volume":"12","author":"van Kampen","year":"2021","journal-title":"Nat Commun"},{"issue":"7809","key":"10.1016\/j.ebiom.2023.104683_bib22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"Wolfel","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104683_bib23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1473-3099(21)00648-4","article-title":"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study","volume":"22","author":"Singanayagam","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104683_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2107058","article-title":"Prevention and attenuation of covid-19 with the BNT162b2 and mRNA-1273 vaccines","volume":"385","author":"Thompson","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"38","key":"10.1016\/j.ebiom.2023.104683_bib25","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2106433118","article-title":"Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques","volume":"118","author":"King","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"10.1016\/j.ebiom.2023.104683_bib26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","article-title":"A\u00a0robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples","volume":"366","author":"Ackerman","year":"2011","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.ebiom.2023.104683_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.07.002","article-title":"A\u00a0high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation","volume":"473","author":"Fischinger","year":"2019","journal-title":"J\u00a0Immunol Methods"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104683_bib28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41591-022-02162-x","article-title":"Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster","volume":"29","author":"Kurhade","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104683_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1473-3099(22)00792-7","article-title":"Effect of hybrid immunity and bivalent booster vaccination on Omicron sublineage neutralisation","volume":"23","author":"Hoffmann","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104683_bib30","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.cell.2022.03.019","article-title":"Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and delta variants","volume":"185","author":"Servellita","year":"2022","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104683_bib31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"issue":"7898","key":"10.1016\/j.ebiom.2023.104683_bib32","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104683_bib33","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1093\/cid\/ciab1041","article-title":"Neutralization of severe acute respiratory syndrome coronavirus 2 Omicron variant by sera from BNT162b2 or CoronaVac vaccine recipients","volume":"75","author":"Lu","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"7898","key":"10.1016\/j.ebiom.2023.104683_bib34","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","article-title":"Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron","volume":"602","author":"Carreno","year":"2022","journal-title":"Nature"},{"issue":"6581","key":"10.1016\/j.ebiom.2023.104683_bib35","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.abn7591","article-title":"Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera","volume":"375","author":"Muik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2023.104683_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.957107","article-title":"Mucosal immunity: the missing link in comprehending SARS-CoV-2 infection and transmission","volume":"13","author":"Russell","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2023.104683_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953949","article-title":"mRNA vaccination drives differential mucosal neutralizing antibody profiles in naive and SARS-CoV-2 previously-infected individuals","volume":"13","author":"Longet","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104683_bib38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2500\/aap.2022.43.220045","article-title":"Salivary and serum IgA and IgG responses to SARS-CoV-2-spike protein following SARS-CoV-2 infection and after immunization with COVID-19 vaccines","volume":"43","author":"Li","year":"2022","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.ebiom.2023.104683_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add4853","article-title":"Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination","volume":"7","author":"Tang","year":"2022","journal-title":"Sci Immunol"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104683_bib40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3390\/pathogens11040397","article-title":"Mucosal antibody response to SARS-CoV-2 in paediatric and adult patients: a longitudinal study","volume":"11","author":"Chan","year":"2022","journal-title":"Pathogens"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104683_bib41","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202115326","article-title":"BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?","volume":"14","author":"Darwich","year":"2022","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104683_bib42","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1038\/s41467-022-32389-8","article-title":"SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals","volume":"13","author":"Sano","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2023.104683_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2021.104765","article-title":"Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection","volume":"136","author":"Van Elslande","year":"2021","journal-title":"J\u00a0Clin Virol"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104683_bib44","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3201\/eid2704.204554","article-title":"Persistence of SARS-CoV-2 N-antibody response in healthcare workers, London, UK","volume":"27","author":"Shrotri","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"10.1016\/j.ebiom.2023.104683_bib45","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1080\/23744235.2021.1893378","article-title":"Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies","volume":"53","author":"Garritsen","year":"2021","journal-title":"Infect Dis"},{"key":"10.1016\/j.ebiom.2023.104683_bib46","first-page":"397","article-title":"The humoral immune response more than one year after SARS-CoV-2 infection: low detection rate of anti-nucleocapsid antibodies via Euroimmun ELISA","volume":"11","author":"Paul","year":"2022","journal-title":"Infection"},{"key":"10.1016\/j.ebiom.2023.104683_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103561","article-title":"Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection","volume":"71","author":"Gallais","year":"2021","journal-title":"EBioMedicine"},{"issue":"6529","key":"10.1016\/j.ebiom.2023.104683_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104683_bib49","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12916-021-02144-9","article-title":"Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19-a prospective multicenter cohort study","volume":"19","author":"Kohler","year":"2021","journal-title":"BMC Med"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104683_bib50","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.7326\/M22-1300","article-title":"Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"175","author":"Follmann","year":"2022","journal-title":"Ann Intern Med"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423002487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423002487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:24:22Z","timestamp":1762457062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396423002487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":50,"alternative-id":["S2352396423002487"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104683","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Humoral immune responses associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US military population","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104683"}}